Living without aprotinin: The results of a 5-year blood saving program in cardiac surgery

Acta Anaesthesiologica Scandinavica

Volumn 53, Issue 5, 2009, Pages 573-580

  Ranucci, M ^a   Castelvecchio, S ^a   Romitti, F ^a   IsgrO G ^a   Ballotta, A ^a   Conti, D ^a  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; DESMOPRESSIN; FRESH FROZEN PLASMA; HEPARIN; TRANEXAMIC ACID;

ADULT; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD TRANSFUSION; CLINICAL PROTOCOL; DATA BASE; ERYTHROCYTE CONCENTRATE; HEART SURGERY; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY;

ADULT; AGED; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD COAGULATION; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; CORONARY ARTERY BYPASS; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; HEMOSTASIS; HEPARIN; HUMANS; INTENSIVE CARE UNITS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDIES; THROMBELASTOGRAPHY; TRANEXAMIC ACID; YOUNG ADULT;

EID: 64849100826     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2008.01899.x     Document Type: Article

References (22)

1. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987 2 (8571) : 1289 91.
2. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJM, Briet E, Buller HR. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999 354 : 1940 7.
3. Mangano DT, Tudor IC, Dietzel C. For the Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006 354 : 353 5.
4. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J. For the Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007 297 : 471 9.
5. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R. For the BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008 358 : 2319 31.
6. Ranucci M, Isgrò G. Minimally invasive cardiopulmonary bypass: does it really change the outcome? Crit Care 2007 11 (2) : R45.
7. Casati V, Guzzon D, Oppizzi M, Bellotti F, Franco A, Gerli C, Cossolini M, Torri G, Calori G, Benussi S, Alfieri O. Tranexamic acid compared with high-dose aprotinin in primari elective heart operations: effects on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg 2000 120 : 520 7.
8. Casati V, Guzzon D, Oppizzi M, Cossolini M, Torri G, Calori G, Alfieri O. Hemostatic effects of aprotinin, tranexamic acid and ε-aminocaproic acid in primary cardiac surgery. Ann Thorac Surg 1999 68 : 2252 7.
9. Despotis GJ, Joist JH, Hogue CW Jr., Alsoufiev A, Joiner-Maier D, Santoro SA, Spitznagel E, Weitz JL, Goodnough LT. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996 76 : 902 8.
10. Despotis GJ, Levine V, Saleem R, Spitznagel E, Joist JH. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet 1999 354 : 106 10.
11. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999 88 : 312 9.
12. Liebold A, Khosravi A, Westphal B, Skrabal C, Choi YH, Stamm C, Kaminski A, Alms A, Birken T, Zurakowski D, Steinhoff G. Effect of closed minimized cardiopulmonary bypass on cerebral tissue oxygenation and microembolization. J Thorac Cardiovasc Surg 2006 131 : 268 76.
13. Perthel M, El-Ayoubi L, Bendisch A, Laas J, Gerigk M. Clinical advantages of using mini-bypass systems in terms of blood product use, postoperative bleeding and air entrainment: an in vivo clinical perspective. Eur J Cardiothorac Surg 2007 31 : 1070 5.
14. Wong BI, McLean RF, Fremes SE, Deemar KA, Harrington EM, Cristakis GT, Goldman BS. Aprotinin and tranexamic acid for high transfusion risk cardiac surgery. Ann Thorac Surg 2000 69 : 808 16.
15. Jamieson WR, Dryden PJ, O'Connor JP, Sadeghi H, Ansley DM, Merrick PM. Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery. Circulation 1997 96 (9 Suppl.) : 96 100.
16. Dietrich W, Busley R, Kriner M. High-dose aprotinin in cardiac surgery: is high-dose high enough? An analysis of 8281 cardiac surgical patients treated with aprotinin. Anesth Analg 2006 103 : 1074 81.
17. Taggart DP, Djapardy V, Naik M, Davies A. A randomized trial of aprotinin (trasylol) on blood loss, blodd product requirement, and myocardial injury in total arterial grafting. J Thorac Cardiovasc Surg 2003 126 : 1087 94.
18. Fraedrich G, Weber C, Bernard C, Hettwer A, Schlosser V. Reduction of blood transfusion requirement in open heart surgery by administration of high-doses of aprotinin - preliminary results. J Thorac Cardiovasc Surg 1989 37 : 89 91.
19. Dietrich W, Barankay A, Hahnel C, Richter JA. High-dose aprotinin in cardiac surgery: three years' experience in 1784 patients. J Cardiothorac Vasc Anesth 1992 6 : 324 7.
20. Murkin JM, Lux J, Shannon NA, Guiraudon GM, Menkis AH, McKenzie FN, Novick RJ. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994 107 : 554 61.
21. Diprose P, Herbertson MJ, O'Shaughnessy D, Deakin CD, Gill RS. Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibronolytic therapies used in addition to intra-operative cell salvage. Br J Anaesth 2005 94 : 271 8.
22. Ranucci M. Perioperative haemostasis and coagulation management in cardiac surgery: a European survey. Eur J Anaesth 2007 24 (Suppl. 40) : 1 13.